News3 mins ago
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
Cyltezo® (adalimumab-adbm) expands treatment options for patients across multiple chronic inflammatory diseases Cyltezo is the only adalimumab biosimilar with Phase III comparative clinical studies in rheumatoid...
